Aura Biosciences (AURA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AURA Aura Biosciences

Watchlist

9.030
+0.280+3.20%

Close Nov 21 16:00 ET

9.030
0.0000.00%

Post 16:20 ET

451.06MMarket Cap-5219P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BTIG Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsNov 14 08:35 ET · Ratings
Scotiabank Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23
Moomoo NewsNov 14 08:35 ET · Ratings
Aura Biosciences Analyst Ratings
BenzingaNov 14 05:08 ET · Ratings
TD Cowen Maintains Aura Biosciences(AURA.US) With Buy Rating
Moomoo NewsNov 13 00:32 ET · Ratings
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23
Moomoo NewsNov 12 22:31 ET · Ratings
Buy Rating for Aura Biosciences Inc Driven by Promising Clinical Progress and Strategic Growth
TipRanksNov 12 22:05 ET · Ratings

Comments

Thatmyname

Oct 18 08:25

$Aura Biosciences (AURA.US)$ Thisssss

Trytosaveabit

Oct 17 15:10

News

$Aura Biosciences (AURA.US)$ Reuters· 1 min ago!
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events

Jaguar8

Sep 12 07:23

NEWS

$Aura Biosciences (AURA.US)$
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Aura Biosciences (NASDAQ: AURA) reported positive Phase 2 end of study results for bel-sar (AU-011) in treating early-stage choroidal melanoma (CM). The study showed an 80% tumor control rate and 90% visual acuity preservationamong Phase 3-eligible patients. Bel-sar demonstrated a highly favorable safety profile with no tre...

Stock_Drift

Sep 12 07:09

$Aura Biosciences (AURA.US)$
via @Lnova 📊⚡️📊

Lnova: [Share Link: Aura Biosciences' Eye Cancer Therapy Shows Promise in Mid-Stage Study]

StarGazerr

Sep 12 05:33

$Aura Biosciences (AURA.US)$ 股票代码: AURA.US : Nasdaq;美东时间: 2024/09/12 06:30，Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

AURA Aura Biosciences

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target